Janux Therapeutics, Inc. (JANX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
JANX currently has 62.7M outstanding shares. with significant dilution risk as 38.5M authorized shares could dilute existing holders by 61.4%. The company has diluted shareholders by 16.69% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 62.7M shares outstanding |
63M | 38M |
| Nov 06, 2025 |
10-Q filing | 62.0M shares outstanding |
62M | 38M |
| Aug 07, 2025 |
10-Q filing | 61.9M shares outstanding |
62M | 38M |
| May 08, 2025 |
10-Q filing | 61.8M shares outstanding |
62M | 38M |
| Feb 27, 2025 |
10-K filing | 53.8M shares outstanding |
54M | 38M |
| Nov 06, 2024 |
10-Q filing | 54.6M shares outstanding |
55M | 38M |
| Aug 07, 2024 |
10-Q filing | 54.5M shares outstanding |
54M | 38M |
| May 08, 2024 |
10-Q filing | 49.0M shares outstanding |
49M | 38M |
| Mar 08, 2024 |
10-K filing | 51.7M shares outstanding |
52M | 38M |
| Feb 29, 2024 |
8-K filing: Janux Therapeutics, Inc. announced an underwritten public offering of 4,440,851 shares of common stock at $46.50 per share and pre-funded warrants to purchase 1,935,483 shares at $46.499 per warrant, with an option for underwriters to purchase up to an additional 956,450 shares. ($296.5M proceeds) |
46M | 38M |
| Nov 07, 2023 |
10-Q filing | 45.7M shares outstanding |
46M | 38M |
| Aug 08, 2023 |
10-Q filing | 41.8M shares outstanding |
42M | 38M |
| May 09, 2023 |
10-Q filing | 41.8M shares outstanding |
42M | 38M |
| Mar 10, 2023 |
10-K filing | 41.5M shares outstanding |
41M | 38M |
| Nov 10, 2022 |
10-Q filing | 41.5M shares outstanding |
42M | 38M |
| Aug 09, 2022 |
10-Q filing | 41.4M shares outstanding |
41M | 38M |
| Aug 09, 2022 |
S-3 filing: The company may offer and sell up to $400,000,000 of any combination of shares of our common stock, shares of our preferred stock, debt securities and warrants to purchase any of such securities, in one or more offerings as described in this prospectus. |
42M | 38M |
| May 10, 2022 |
10-Q filing | 41.6M shares outstanding |
42M | 9.5M |
| Mar 18, 2022 |
10-K filing | 41.6M shares outstanding |
42M | 9.5M |
| Nov 09, 2021 |
10-Q filing | 41.6M shares outstanding |
42M | 9.5M |
| Aug 10, 2021 |
10-Q filing | 41.6M shares outstanding |
42M | 9.5M |
| Jun 07, 2021 |
S-1/A filing: Janux Therapeutics, Inc. is offering 9,500,000 shares of its common stock in an initial public offering. The expected initial public offering price is between $15.00 and $17.00 per share. |
N/A | 9.5M |
| May 19, 2021 |
S-1 filing: This is an S-1 filing for the initial public offering of common stock of Janux Therapeutics, Inc. |
N/A | 0 |